Prevention and treatment of congenital toxoplasmosis

Expert Review of Anti-Infective Therapy

Volumn 5, Issue 2, 2007, Pages 285-293

  Petersen, Eskild ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Control; Disease burden; Prevention; Toxoplasma gondii; Treatment

Indexed keywords

ATOVAQUONE; AZITHROMYCIN; CLINDAMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; PLACEBO; PROTOZOON ANTIBODY; PYRIMETHAMINE; PYRIMETHAMINE SULFADIAZINE; SPIRAMYCIN; SULFADIAZINE; SULFONAMIDE; SURFACE WATER;

AMNIOCENTESIS; ANEMIA; ANTIBIOTIC RESISTANCE; ANTIBODY DETECTION; CLINICAL TRIAL; CONGENITAL TOXOPLASMOSIS; COOKING; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG RESEARCH; EARLY DIAGNOSIS; ENVIRONMENTAL SANITATION; EUROPE; FETUS DEATH; FOOD CONTAMINATION; FOOD HANDLING; HEALTH CARE POLICY; HEALTH EDUCATION; HEART ARREST; HUMAN; INFECTION CONTROL; INFECTION RISK; MEAT; MEDICAL DECISION MAKING; MEDICAL RESEARCH; NEUTROPENIA; PERINATAL PERIOD; PLACENTAL TRANSFER; POLYMERASE CHAIN REACTION; PREGNANCY; PRENATAL SCREENING; QT PROLONGATION; REVIEW; SCREENING TEST; SOIL POLLUTION; THEORY; THERAPEUTIC ABORTION; TOXOPLASMA GONDII; TOXOPLASMOSIS; UNSPECIFIED SIDE EFFECT; UVEITIS; WATER CONTAMINATION;

ANIMALS; ANTIPROTOZOAL AGENTS; ATOVAQUONE; FEMALE; FOOD CONTAMINATION; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TOXOPLASMA; TOXOPLASMOSIS, CONGENITAL;

EID: 34247886092     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.5.2.285     Document Type: Review

References (73)

1. Gilbert RE, Dunn DT, Lightman S et al. Incidence of symptomatic toxoplasma eye disease: aetiology and public health implications. Epidemiol. Infect. 123(2), 283-289 (1999).
2. Gilbert R, Tan HK, Cliffe S, Guy E, Stanford M. Symptomatic toxoplasma infection due to congenital and postnatally acquired infection. Arch. Dis. Child. 91(6), 495-498 (2006). (Erratum in: Arch. Dis. Child. 91(7), 625 [2006]).
3. Holland GN. Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease. Am. J. Ophthalmol. 136(6), 973-988 (2003).
4. Bowie WR, King AS, Werker DH et al. Outbreak of toxoplasmosis associated with municipal drinking water. The BC Toxoplasma Investigation Team. Lancet 350(9072), 173-177 (1997).
5. Bahia-Oliveira LM, Jones JL, Azevedo-Silva J, Alves CC, Orefice F, Addiss DG. Highly endemic, waterborne toxoplasmosis in north Rio de Janeiro state, Brazil. Emerg. Infect. Dis. 9(1), 55-62 (2003).
6. Stanford MR, Tan HK, Gilbert R. Toxoplasmic retinochoroiditis presenting in childhood: clinical findings in a UK survey. Br. J. Ophthalmol. 90(12), 1464-1467 (2006).
7. Dubey JP. Sources of Toxoplasma gondii infection in pregnancy. Until rates of congenital toxoplasmosis fall, control measures are essential. Br. Med. J. 321, 127-128 (2000).
8. Hill D, Dubey JP. Toxoplasma gondiì. transmission, diagnosis and prevention. Clin. Microbiol. Infect. 8, 634-640 (2002).
9. Frenkel JK, Ruiz A, Chinchilla M. Soil survival of toxoplasma oocysts in Kansas and Costa Rica. Am. J. Trop. Med. Hyg. 24, 439-443 (1975).
10. Kapperud G, Jenum PA, Stray-Pedersen B, Melby KK, Eskil A, Eng J. Risk factors for Toxoplasma gondii infection in pregnancy. Results of a prospective case-control study in Norway. Am. J. Epidemiol. 144, 405-412 (1996).
11. Buffolano W, Gilbert RE, Holland FJ, Fratta D, Palumbo F, Ades AE. Risk factors for recent toxoplasma infection in pregnant women in Naples. Epidemiol. Infect. 116, 347-351 (1996).
12. Baril L, Ancelle T, Goulet V, Thulliez P, Tirard-Fleury V, Carme B. Risk factors for Toxoplasma infection in pregnancy: a case-control study in France. Scand. J. Infect. Dis. 31, 305-309 (1999).
13. Cook AJ, Gilbert RE, Buffolano W et al. Sources of toxoplasma infection in pregnant women: European multicentre case-control study. European Research Network on Congenital Toxoplasmosis. Br. Med. J. 321, 142-147 (2000).
14. Dubey JP, Hill DF, Jones JL et al. Prevalence of viable Toxoplasma gondii in beef, chicken, and pork from retail meat stores in the United States: risk assessment to consumers. J. Parasitol. 91(5), 1082-1093 (2005).
15. Kotula AW, Dubey JP, Sharar AK, Andrew CD, Shen SK, Lindsay DA. Effect of freezing on infectivity of Toxoplasma gondii tissue cysts in pork. J. Food Protection 54, 687-690 (1991).
16. Kijlstra A, Eissen OA, Cornelissen J, Munniksma K, Eijck I, Kortbeek T. Toxoplasma gondii infection in animal-friendly pig production systems. Invest. Ophthalmol. Vis. Sci. 45(9), 3165-3169 (2004).
17. Conyn-van Spaedonck MA, van Knapen F. Choices in preventive strategies: experience with the prevention of congenital toxoplasmosis in The Netherlands. Scand. J. Infect. Dis. 84(Suppl.), 51-58 (1992).
18. Lopez A, Dietz VJ, Wilson M, Navin TR, Jones JL. Preventing congenital toxoplasmosis. MMWR Recomm. Rep. 49(RR-2), 59-68 (2000).
19. Breugelmans M, Naessens A, Foulon W. Prevention of toxoplasmosis during pregnancy - an epidemiologic survey over 22 consecutive years. J. Perinat. Med. 32(3), 211-214 (2004).
20. Forsgren M, Gille E, Ljungstrom I, Nokes DJ. Toxoplasma gondii antibodies in pregnant women in Stockholm in 1969, 1979, and 1987. Lancet 337(8754), 1413-1414 (1991).
21. Welton NJ, Ades AE. A model of toxoplasmosis incidence in the UK: evidence synthesis and consistency of evidence. JRSS (C) Applied Statistics 54, 385-404 (2005).
22. Remington JS, McLeod R, Thulliez P. Toxoplasmosis. In: Infectious Diseases of the Fetus and Newborn Infant. Remington JS, Klein J (Eds). WB Saunders, PA, USA 205-346 (2001).
23. Wallon M, Liou C, Garner P, Peyron F. Congenital toxoplasmosis: systematic review of evidence of efficacy of treatment in pregnancy. Br. Med. J. 318(7197), 1511-1514 (1999).
24. Gras L, Wallon M, Pollak A et al for the European Multicenter Study on Congenital Toxoplasmosis. Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centres. Acta Paediatr. 94(12), 1721-1731 (2005).
25. Gilbert R, Gras L, European Multicentre Study on Congenital Toxoplasmosis. Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii. BJOG 110, 12-120 (2003).
26. The SYROCOT (Systematic Review on Congenital Toxoplasmosis) Study Group. Individual patient data meta-analysis of prenatal treatment effect for congenital toxoplasmosis. Lancet 369, 115-122 (2007).
27. Aspock H, Pollak A. Prevention of prenatal toxoplasmosis by serological screening of pregnant women in Austria. Scand. J. Infect. Dis. (Suppl. 84), 32-37 (1992).
28. Binquet C, Wallon M, Metral P, Gadreau M, Quantin C, Peyron F. Toxoplasmosis seroconversion in pregnant women. The differing attitudes in France. Presse Med. 33, 775-779 (2004).
29. Thalib L, Gras L, Romand S et al. Prediction of congenital toxoplasmosis by polymerase chain reaction analysis of amniotic fluid. Br. J. Obstet. Gynaecol. 112(5), 567-574 (2005).
30. Romand S, Chosson M, Franck J et al. Usefulness of quantitative polymerase chain reaction in amniotic fluid as early prognostic marker of fetal infection with Toxoplasma gondii. Am. J. Obstet. Gynecol. 190(3), 797-802 (2004).
31. Logar J, Petrovec M, Novak-Antolic Z et al. Prevention of congenital toxoplasmosis in Slovenia by serological screening of pregnant women. Scand. J. Infect. Dis. 34, 201-204 (2002).
32. Foulon W, Villena I, Stray-Pedersen B et al. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year. Am. J. Obstet. Gynecol. 180, 410-415 (1999).
33. Freeman K, Oakley L, Pollak A et al for the European Multicentre Study on Congenital Toxoplasmosis (EMSCOT). Association between congenital toxoplasmosis and preterm birth, low birthweight and small for gestational age. Br. J. Obstet. Gynaecol. 112, 31-37 (2005).
34. Roizen N, Kasza K, Karrison T et al. Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies. Pediatrics 118(2), E379-E390 (2006).
35. Guerina NG, Hsu HW, Meissner HC et al. Neonatal serologic screening and early treatment for congenital T. gondii infection. The New England Regional Toxoplasma Working Group. N. Engl. J. Med. 330, 1858-1863 (1994).
36. Lebech M, Andersen O, Christensen NC et al, Danish Congenital Toxoplasmosis Study Group. Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment. Lancet 353, 1834-1837 (1999).
37. Neto EC, Rubin R, Schulte J, Giugliani R. Newborn screening for congenital infectious diseases. Emerg. Infect. Dis. 10, 1068-1073 (2004).
38. Schmidt DR, Hogh B, Andersen O, Fuchs J, Fledelius H, Petersen E. The national neonatal screening programme for congenital toxoplasmosis in Denmark: results from the initial four years, 1999-2002. Arch. Dis. Child. 91(8), 661-665 (2006).
39. Decoster A, Darcy F, Caron A et al. Anti-P30 IgA antibodies as prenatal markers of congenital toxoplasma infection. Clin. Exp. Immunol. 87, 310-315 (1992).
40. Paul M, Petersen F, Szczapa J. Prevalence of congenital Toxoplasma gondii infection among newborns from the Poznan region of Poland: validation of a new combined enzyme immunoassay for Taxoplasma gondii-specific immunoglobulin A and immunoglobulin M antibodies. J. Clin. Microbiol. 39, 1912-1916 (2001).
41. Janitschke K. Official recommendations and strategy for prevention of congenital toxoplasmosis in Germany. Arch. Pediatr. 10(Suppl.), 15 (2003).
42. Joynson DH. Congenital toxoplasma infection in the UK. Arch. Pediatr. 10(Suppl. 1), 27-28 (2003).
43. Lappalainen M. Current situation regarding toxoplasmosis in Finland. Arch. Pediatr. 10(Suppl. 1), 19 (2003).
44. Stray-Pedersen B. Prevention of congenital toxoplasmosis in Norway. Arch. Pediatr. 10(Suppl. 1), 23-24 (2003).
45. Villena I, Aubert D, Leroux B et al. Pyrimethamine-sulfadoxine treatment of congenital toxoplasmosis: follow-up of 78 cases between 1980 and 1997. Reims Toxoplasmosis Group. Scand. J. Infect. Dis. 30, 295-300 (1998).
46. Signorell LM, Seitz D, Merkel S, Berger R, Rudin C. Cord blood screening for congenital toxoplasmosis in northwestern Switzerland, 1982-1999. Pediatr. Infect. Dis. J. 25(2), 123-128 (1996).
47. Petersen E, Schmidt DR. Sulfadiazine and pyrimethamine in the postnatal treatment of congenital toxoplasmosis: what are the options? Expert Rev. Anti Infect. Ther. 1, 175-182 (2003).
48. Couvreur J, Nottin N, Desmonts G. La toxoplasmose congenitale traitee. Resultats cliniques et biologiques. Ann. Pediatr. (Paris) 27(10), 647-652 (1980).
49. Gilbert RE, Dunn D, Wallon M et al. Ecological comparison of the risks of mother-to-child transmission and clinical manifestations of congenital toxoplasmosis according to prenatal treatment period. Epidemiol. Infect. 127, 113-120 (2001).
50. Wallon M, Kodjikian L, Binquet C et al. Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics 113(6), 1567-1572 (2004).
51. Mets MB, Holfels E, Boyer KM et al. Eye manifestations of congenital toxoplasmosis. Am. J. Ophthalmol. 122(3), 309-324 (1996).
52. Wallon M, Cozon G, Ecochard R, Lewin P, Peyron F. Serological rebound in congenital toxoplasmosis: long-term follow-up of 133 children. Eur. J. Pediatr. 160, 534-540 (2001).
53. McAuley J, Boyer KM, Patel D et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. Clin. Infect. Dis. 18(1), 38-72 (1994).
54. McLeod R, Boyer K, Karrison T et al, the Toxoplasmosis Study Group. Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin. Infect. Dis. 42(10), 1383-1394 (2006).
55. Perkins ES, Schofield PB, Smith CH. Treatment of uveitis with pyrimethamine (daraprim). Br. J. Ophthalmol. 40, 577-586 (1956).
56. Rothova A, Meenken C, Buitenhuis HJ et al. Therapy for ocular toxoplasmosis. Am. J. Ophthalmol. 115, 517-523 (1993).
57. Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MS et al. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am. J. Ophthalmol. 134, 34-40 (2002).
58. Silveira C, Belfort R Jr, Muccioli C et al. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am. J. Ophthalmol. 134, 41-46 (2002).
59. Schmidt DR, Høgh B, Andersen O, Hansen SH, Dalhoff K, Petersen E. Treatment of infants with congenital toxoplasmosis: tolerability and plasma concentrations of sulfadiazine and pyrimethamine. Eur. J. Pediatr. 165(1), 19-25 (2006).
60. Stramba-Badiale M, Nador F, Porta N et al. QT interval prolongation and risk of life-threatening arrhythmias during toxoplasmosis prophylaxis with spiramycin in neonates. Am. Heart J. 133(1), 108-111 (1997).
61. Ferguson DJ, Huskinson-Mark J, Araujo FG, Remington JS. An ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii. Int. J. Exp. Pathol. 75(2), 111-116 (1994).
62. Gormley PD, Pavesio CE, Minnasian D, Lightman S. Effects of drug therapy on Toxoplasma cysts in an animal model of acute and chronic disease. Invest. Ophthalmol. Vis. Sci. 39, 1171-1175 (1998).
63. Araujo FG, Khan AA, Bryskier A, Remington JS. Use of ketolides in combination with other drugs to treat experimental toxoplasmosis. J. Antimicrob. Chemother. 42, 665-667 (1998).
64. Djurkovic-Djakovic O, Milenkovic V, Nikolic A, Bobic B, Grujic J. Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii. J. Antimicrob. Chemother. 50(6), 981-987 (2002).
65. Alves CF, Vitor RW. Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil. Parasite 12(2), 171-177 (2005).
66. McFadden DC, Camps M, Boothroyd JC. Resistance as a tool in the study of old and new drug targets in Toxoplasma. Drug Resist. Updat. 4(2), 79-84 (2001).
67. Huskinson-Mark J, Araujo FG, Remington JS. Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J. Infect. Dis. 164, 170-171 (1991).
68. Derouin F, Caroff B, Chau F, Prokocimer P, Pocidalo JJ. Synergistic activity of clarithromycin and minocycline in an animal model of acute experimental toxoplasmosis. Antimicrob. Agents Chemother. 36, 2852-2855 (1992).
69. Caramello P, Brancale T, Forno B et al. Relapse of Toxoplasma encephalitis and susceptibility to pyrimethamine: lack of evidence of treatment-induced resistance. Antimicrob. Agents Chemother. 39(10), 2371-2372 (1995).
70. Pfefferkorn ER, Borotz SE, Nothnagel RF. Toxoplasma gondii: characterization of a mutant resistant to sulfonamides. Exp. Parasitol. 74(3), 261-270 (1992).
71. Aspinall TV, Joynson DH, Guy E, Hyde JE, Sims PF. The molecular basis of sulfonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis. J. Infect. Dis. 185(11), 1637-1643 (2002).
72. Peyron F, Eudes N, de Monbrison F, Wallon M, Picot S. Fitness of Toxoplasma gondii is not related to DHFR single-nucleotide polymorphism during congenital toxoplasmosis. Int. J. Parasitol. 34(10), 1169-1175 (2004).
73. Reynolds MG, Roos DS. A biochemical and genetic model for parasite resistance to antifolates. Toxoplasma gondii provides insights into pyrimethamine and cycloguanil resistance in Plasmodium falciparum. J. Biol. Chem. 273(6), 3461-3469 (1998).